Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates.
The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth greater than 30% from the previous year, compared to the previous suggestion of greater than 25%.
Shares of Insulet fell more than 10% to $149 apiece before the market opened today.
The Acton, Massachusetts-based automated insulin delivery technology developer reported profits of $95 million. That equals $1.37 per share on sales of $801.7 million for the three months ended June 30, 2026.
Insulet more than quadrupled its profits on a sales increase of 23.5%.
Get the full story at our sister site, Drug Delivery Business News.
